doi: 10.1056/NEJMsb2104756.
SARS-CoV-2 Variants in Patients with Immunosuppression
Affiliations
- PMID: 34347959
- PMCID: PMC8494465
- DOI: 10.1056/NEJMsb2104756
Item in Clipboard
SARS-CoV-2 Variants in Patients with Immunosuppression
N Engl J Med.
.
Free PMC article
No abstract available
Figures
Panel A shows the spike protein structure of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (entry 6ZGE in the Worldwide Protein Data Bank [PDB]). Domains are colored according to their role in viral entry and antibody recognition; the terminal domain that is missing in 6ZGE is shaded in gray. As shown in the graphic above the chart, the spike protein consists of two subunits, with subunit 1 (S1) (the portions in yellow, purple, blue, green, and pink) containing the receptor-binding domain (RBD), the N-terminal domain (NTD), and several other subdomains and subunit 2 (S2) (the portion in gray) mediating fusion of the virus-cell membrane. Also shown are the spike mutations that are representative of circulating variants of concern (B.1.1.7, B.1.351, P.1, and B.1.617.2) or variants of interest (B.1.427/429, B.1.525, and B.1.526), as well as patterns of mutations identified over the course of persistent infections in immunocompromised patients, as described in case reports. Representative sequences from the case reports are listed according to the first author’s name (,,,,). Mutations in the NTD super- site are located nearby on the protein structure. Mutations are also recurring in the receptor-binding motif (RBM) and around the furin cleavage site. The symbols at the top of the columns indicate the N-linked glycosylation sites. CD denotes connector domain, CH center helix, CT cytoplasmic tail, HR1 heptad repeat 1, HR2 heptad repeat 2, SD1 subdomain 1, SD2 subdomain 2, S2′FP S2 fusion peptide, and TM transmembrane. Panel B shows the phylogenetic tree of 1510 SARS-CoV-2 viruses detected in patients in the United Kingdom between January 2020 and February 2021. The phylogeny is embedded as a root-to-tip plot, in which the x axis represents the date of sample collection and the y axis represents the number of genomewide mutations that have occurred since the phylogeny root. The phylogeny is colored according to the clade, as listed in the Nextstrain database (an online site for the sharing of sequencing and genomic data about SARS-CoV-2). Clade 20I/501Y.V1 in this database corresponds to lineage B.1.1.7 in the Phylogenetic Assignment of Named Global Outbreak Lineages (PANGO) and is colored in orange and annotated in the figure. The branch leading to lineage B.1.1.7 is annotated with selected mutations that are present along this single branch. Lineage B.1.1.7 has a higher number of mutations than most other circulating viruses and has rapidly displaced existing genetic diversity in the United Kingdom. The phylogeny is constructed from sequence data shared to GISAID (a database of genomic information regarding influenza viruses and coronaviruses) by means of methods implemented by Nextstrain.
Panel A shows the spike protein structure of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (entry 6ZGE in the Worldwide Protein Data Bank [PDB]). Domains are colored according to their role in viral entry and antibody recognition; the terminal domain that is missing in 6ZGE is shaded in gray. As shown in the graphic above the chart, the spike protein consists of two subunits, with subunit 1 (S1) (the portions in yellow, purple, blue, green, and pink) containing the receptor-binding domain (RBD), the N-terminal domain (NTD), and several other subdomains and subunit 2 (S2) (the portion in gray) mediating fusion of the virus-cell membrane. Also shown are the spike mutations that are representative of circulating variants of concern (B.1.1.7, B.1.351, P.1, and B.1.617.2) or variants of interest (B.1.427/429, B.1.525, and B.1.526), as well as patterns of mutations identified over the course of persistent infections in immunocompromised patients, as described in case reports. Representative sequences from the case reports are listed according to the first author’s name (,,,,). Mutations in the NTD super- site are located nearby on the protein structure. Mutations are also recurring in the receptor-binding motif (RBM) and around the furin cleavage site. The symbols at the top of the columns indicate the N-linked glycosylation sites. CD denotes connector domain, CH center helix, CT cytoplasmic tail, HR1 heptad repeat 1, HR2 heptad repeat 2, SD1 subdomain 1, SD2 subdomain 2, S2′FP S2 fusion peptide, and TM transmembrane. Panel B shows the phylogenetic tree of 1510 SARS-CoV-2 viruses detected in patients in the United Kingdom between January 2020 and February 2021. The phylogeny is embedded as a root-to-tip plot, in which the x axis represents the date of sample collection and the y axis represents the number of genomewide mutations that have occurred since the phylogeny root. The phylogeny is colored according to the clade, as listed in the Nextstrain database (an online site for the sharing of sequencing and genomic data about SARS-CoV-2). Clade 20I/501Y.V1 in this database corresponds to lineage B.1.1.7 in the Phylogenetic Assignment of Named Global Outbreak Lineages (PANGO) and is colored in orange and annotated in the figure. The branch leading to lineage B.1.1.7 is annotated with selected mutations that are present along this single branch. Lineage B.1.1.7 has a higher number of mutations than most other circulating viruses and has rapidly displaced existing genetic diversity in the United Kingdom. The phylogeny is constructed from sequence data shared to GISAID (a database of genomic information regarding influenza viruses and coronaviruses) by means of methods implemented by Nextstrain.
Similar articles
-
COVID-19 Updates: Monoclonal Antibodies for COVID-19.Med Lett Drugs Ther. 2022 Jan 24;64(1642):16. Med Lett Drugs Ther. 2022. PMID: 35139286 No abstract available.
-
Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.Int J Infect Dis. 2021 Mar;104:379-381. doi: 10.1016/j.ijid.2020.12.050. Epub 2020 Dec 21. Int J Infect Dis. 2021. PMID: 33359065 Free PMC article.
-
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant.N Engl J Med. 2022 Mar 10;386(10):995-998. doi: 10.1056/NEJMc2119407. Epub 2022 Jan 26. N Engl J Med. 2022. PMID: 35081300 Free PMC article. No abstract available.
-
An EUA for bamlanivimab and etesevimab for COVID-19.Med Lett Drugs Ther. 2021 Apr 5;63(1621):49-50. Med Lett Drugs Ther. 2021. PMID: 33830966 No abstract available.
-
New SARS-CoV-2 Variants Challenge Vaccines Protection.AIDS Rev. 2021 Feb 22;23(1):57-58. doi: 10.24875/AIDSRev.M21000040. AIDS Rev. 2021. PMID: 33750742 No abstract available.
Cited by
-
The SARS-CoV-2 Antibodies, Their Diagnostic Utility, and Their Potential for Vaccine Development.Vaccines (Basel). 2022 Aug 18;10(8):1346. doi: 10.3390/vaccines10081346. Vaccines (Basel). 2022. PMID: 36016233 Free PMC article. Review.
-
Synthesis and In Silico Docking Study towards M-Pro of Novel Heterocyclic Compounds Derived from Pyrazolopyrimidinone as Putative SARS-CoV-2 Inhibitors.Molecules. 2022 Aug 19;27(16):5303. doi: 10.3390/molecules27165303. Molecules. 2022. PMID: 36014537 Free PMC article.
-
Role of the Pangolin in Origin of SARS-CoV-2: An Evolutionary Perspective.Int J Mol Sci. 2022 Aug 14;23(16):9115. doi: 10.3390/ijms23169115. Int J Mol Sci. 2022. PMID: 36012377 Free PMC article.
-
Immune Heterogeneity and Epistasis Explain Punctuated Evolution of SARS-CoV-2.medRxiv. 2022 Jul 29:2022.07.27.22278129. doi: 10.1101/2022.07.27.22278129. Preprint. medRxiv. 2022. PMID: 35982659 Free PMC article.
-
Current Advances in Paper-Based Biosensor Technologies for Rapid COVID-19 Diagnosis.Biochip J. 2022 Aug 10:1-21. doi: 10.1007/s13206-022-00078-9. Online ahead of print. Biochip J. 2022. PMID: 35968255 Free PMC article. Review.
MeSH terms
Substances
Grant support
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous